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Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous group of cancers 
originating from the aerodigestive epithelium of the upper respiratory tract. Although 
survival rates are improving, treatment outcome in certain patient subgroups is still 
disappointing. Molecular markers, such as p16, a surrogate marker for Human 
Papilloma Virus infection, and Epidermal Growth Factor Receptor (EGFR) have been 
suggested as relevant for prediction of treatment outcome. Another molecular marker 
under investigation is the single nucleotide polymorphism rs1800470 of the 
Transforming Growth Factor β1 gene (TGFB1) that affects levels of the pleiotrophic 
cytokine TGFβ1, an essential regulator of cell proliferation, immunomodulation, and 
cancer stem cell maintenance. The aim of this thesis was to investigate the value of 
these molecular markers in HNSCC, and their potential relation to treatment outcome. 
Furthermore, as the incidence of oropharyngeal cancer (OPSCC) is rapidly increasing in 
several western countries, we surveyed its relation to a possible increase in p16 
overexpression in HNSCC in Finland.  
Peripheral blood from a cohort of 175 consecutive patients was genotyped for 
rs1800470 of TGFB1 by polymerase chain reaction (PCR), and expression of p16 and 
EGFR explored with immunohistochemistry. The results were correlated with clinical 
and histopathological variables. The Finnish Cancer Registry provided data on OPSCC 
incidence.  
Age-standardized incidence in Finland of OPSCC was increasing and likewise the 
proportion of p16 overexpressing HNSCC. Overexpression of p16 was associated with 
improved survival in OPSCC, but with no association between EGFR expression and 
survival. The variant allele of TGFB1 at rs1800470 was associated with improved 
outcome, especially in OPSCC, and in tumors treated with chemoradiotherapy. This 
result was not explainable by a decreased grade of chemoradiotherapy-induced acute 
mucositis or by altered treatment time. Improved survival was independent of p16 and 
EGFR expression, although carriers of the variant allele were more liable to have a p16-
overexpressing tumor. 
In HNSCC, the single nucleotide polymorphism rs1800470 of TGFB1 is a potential 
independent prognostic marker that can, in combination with p16 expression, predict 




Cancer i huvud- och halsregionen (HNSCC) är en heterogen grupp cancertyper vilka 
utgår främst från skivepitelet i de övre luftvägarna. De viktigaste kända riskfakorerna 
för HNSCC är rökning, stort alkoholbruk och infektion med humant papillomvirus 
(HPV). Trots att man gjort framsteg inom behandlingen är prognosen för överlevnad 
fortfarande nedslående hos vissa patientgrupper. För att kunna optimera behandlingen 
på ett individuellt plan och förutspå överlevnaden har man föreslagit att molekylära 
markörer kunde vara användbara. Exempel på dessa är p16, en surrogatmarkör för 
infektion med HPV, och den epidermala tillväxtfaktorreceptorn EGFR. En annan 
intressant markör är den nukleära polymorfismen rs1800470 i genen för tillväxtfaktorn 
”Transforming growth factor β1” (TGFB1). Denna polymorfism påverkar halten av 
TGFβ1, en cytokin som är avgörande för cellproliferation, immunomodulering och för 
upprätthållandet av cancerstamceller. Målet med denna avhandling var att undersöka 
dessa markörer hos patienter med HNSCC och om man med deras hjälp kan förutspå 
behandlingsförloppet. Eftersom incidensen för orofaryngealcancer (OPSCC) ökar i 
västvärlden undersökte vi om den ökar också i Finland, samt om denna eventuella 
ökning korrelerar med en förhöjd prevalens i p16-positiv HNSCC. 
I studierna inkluderades 175 konsekutiva HNSCC-patienter vars blod genotypades för 
TGFB1 rs1800470 med polymeras-kedjereaktion (PCR). Vi bestämde p16- och EGFR-
expressionerna med immunohistokemi. Alla resultat korrelerades med kliniska och 
histopatologiska karakteristika. Det finländska cancerregistret tillhandahöll 
incidensuppgifter.  
Den åldersstandardiserade OPSCC-incidensen ökade i Finland, liksom proportionen 
HNSCC som överexpresserade p16. OPSCC-patienter vars tumörer överexpresserade 
p16 hade en förbättrad överlevnad, men något samband mellan EGFR-expression och 
överlevnad kunde inte påvisas. 
OPSCC-patienter som bar på variantallelen av TGFB1 rs1800470 hade signifikant bättre 
överlevnad än patienter med normalallelen. Detsamma gällde för patienter som 
behandlats med chemoradioterapi. Fenomenen kunde inte förklaras med att dessa 
patienter skulle ha fått behandlingsorsakad akut infammation av munslemhinnan i lägre 
grad, eller av att deras behandlingstid skulle ha varit kortare. Den förbättrade 
överlevnaden var oavhängig p16 och EGFR expressioner, även om patienter som bar på 
TGFB1-variantallelen i aningen högre grad hade p16 överexpresserande tumörer.  
Polymorfismen TGFB1 rs1800470 är en potentiell självständig ny prognostisk markör 
som eventuellt, i kombination med p16-expression, kan användas för att förutspå en 
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Head and neck squamous cell carcinoma (HNSCC) is the world’s sixth most common 
cancer, accounting annually for 356 000 deaths (Globocan, 2008). Because of its 
nonspecific symptoms and the difficulty in examining epithelial linings in this area, 
diagnosis is often delayed, and patients at first presentation frequently show with locally 
disseminated disease. That the cure rates of high-stage, extra-capsular spread, and 
recurrent disease are poor (Wong et al. 1996; Thomas et al. 2005), and 5-year overall 
survival remains low (66%)
 
(Pulte and Brenner 2010), makes it essential to diagnose 
HNSCC early and strive for permanent control with primary treatment. 
 
Currently, treatment strategies rely on traditional clinical, histopathological, and 
radiological characteristics to determine disease stage according to a T (tumor), N 
(node), M (metastasis) classification system. Limitations to this approach exist, 
however, because the TNM classification neglects the tumor’s biological characteristics 
such as human papilloma virus (HPV) as a causative agent. The HPV-induced subtype 
is associated with a favorable outcome, which is why HPV status, or possibly its 
surrogate marker p16, has become an important biomarker (Chaturvedi et al. 2011; 
O'Rorke et al. 2012). 
 
Treatment has long been based on surgery and radiotherapy (RT) or a combination of 
these modalities. RT with concomitant chemotherapy (CT) has – because of its equal 
effectiveness yet fewer adverse effects, in addition to its use as an adjuvant, 
postoperative alternative – increasingly replaced surgery as primary treatment for some 
subsites (Argiris et al. 2008; Singh and Pfister 2008; Pignon et al. 2009). The ultimate 
goal of non-invasive treatment schemes is to eradicate the pluripotent, self-renewing, 
and refractile cancer stem cells (CSC) that can remain quiescent after treatment and 
cause relapse (Prince and Ailles 2008). In breast cancer, one of the controlling agents of 
CSCs is Transforming Growth Factor β (TGFβ) (Shipitsin et al. 2007). TGFβ plays an 
essential role in maintaining cell homeostasis, and in processes such as proliferation, 
immunosuppression, and apoptosis (Blobe et al. 2000; Akhurst 2004; Caja et al. 2012). 
The single nucleotide polymorphism rs1800470 of the TGFβ1 gene (TGFB1) elevates 
levels of the most abundant isoform of TGFβ; TGFβ1 (Awad et al. 1998; Yokota et al. 
2000; Dunning et al. 2003), and has been associated with increased risk for breast 
cancer and nasopharyngeal carcinoma (NPC) (Dunning et al. 2003; Wei et al. 2007), 
and decreased survival in various tumors including breast- and esophageal cancer 
(Fukuchi et al. 2004; Shu et al. 2004). Its role as a prognostic marker in HNSCC seems 
to have undergone no prior investigation.  
 
One prognostic marker currently receiving much attention is the epidermal growth 
factor receptor (EGFR), because its genetic mutations and expression profile serve as 
markers of treatment response to EGFR inhibitors in colon- and non-small-cell lung 
cancer. In HNSCC, the EGFR monoclonal antibody cetuximab serves primarily in the 
treatment of disseminated or relapsed disease in combination with RT or 
chemoradiotherapy (CRT), but since 90% of HNSCC cases overexpress EGFR, thus far 
no patient selection is possible based on its expression (Kalyankrishna and Grandis 




A search is ongoing for new biomarkers to guide the clinician towards an optimal 
individualized treatment strategy with a high survival rate and reasonable side-effects. 
This thesis focuses on the potential prognostic biomarkers p16, EGFR, and TGFB1 
rs1800470 to further improve treatment strategies in HNSCC.  
12 
 
REVIEW OF THE LITERATURE 
Epidemiology and risk factors 
Head and neck cancer is made up of a heterogeneous group of tumors. Their clinical 
patterns differ, although 90% arise from squamous epithelial cells of the upper 
aerodigestive tract. HNSCC is classified according to the anatomical site of origin. The 
most common location is the larynx, followed by the oral cavity and the oropharynx 
(Carvalho et al. 2005; Pulte and Brenner 2010). This thesis discusses HNSCC 




Figure 1 Topography of head and neck squamous cell carcinoma subsites discussed here. 
Illustration by Marie Lundberg and Jenny Kuisma. 
In 2009, 724 new HNSCC cases were diagnosed in Finland, equaling an incidence of 11 
per 100 000 person-years (Cancer Statistics, NORDCAN). In the USA the incidence is 
similar; 15 among men and 6 per 100 000 among women (Pulte and Brenner 2010). 
Average age at diagnosis is 60, although this age has, during the last three decades, 
decreased slightly (Argiris et al. 2008; Pulte and Brenner 2010). Overall incidence has 
also decreased in the western world, whereas in many developing countries it is on the 
rise (Warnakulasuriya 2009). This decrease occurs despite a growing number of cancers 
found in the oral tongue, base of the tongue, and the palatine tonsils, particularly among 
young people (Carvalho et al. 2005; Shiboski et al. 2005; Hammarstedt et al. 2007; 
Chaturvedi et al. 2008; Attner et al. 2010; Annertz et al. 2012). The decrease has been 
attributed to a lower prevalence of smoking, one of the major risk factors for HNSCC. 
The other major risk factor is alcohol, and together the two have a multiplicative effect 
(Pai and Westra 2009). Minor risk factors are poor dental hygiene, low socio-economic 
status, smokeless tobacco, betel-nut chewing, family history, certain occupational 
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factors, and infections such as Epstein-Barr virus infection (Rosenquist et al. 2005; 
Argiris et al. 2008; Pai and Westra 2009). 
 
It has become evident that infection with HPV is a third major risk factor for HNSCC 
(Gillison et al. 2000; Syrjanen 2010). The incidence of HPV-associated cancer is 
highest in cancer of the tonsils and the base of the tongue (Kreimer et al. 2005; Syrjanen 
2005; Hobbs et al. 2006; Koskinen et al. 2007; Pai and Westra 2009; Machado et al. 
2010). HPV can possibly also cause oral squamous cell carcinoma (OSCC), as reported 
in a recent meta-analysis (Syrjanen et al. 2011), but for other types of HNSCC, 
causation remains unestablished (Torrente et al. 2011; Lewis et al. 2012; Wilson et al. 
2012). Of oropharyngeal squamous cell carcinoma (OPSCC), 20 to 90% is estimated to 
be related to HPV infection (Hansson et al. 2005; Hammarstedt et al. 2006; Ragin and 
Taioli 2007; Attner et al. 2010), generally to HPV16 (>80%) and less generally to 
HPV18, 31, or 33 (Kreimer et al. 2005). These are the same oncogenic viruses that 
induce anogenital cancers (Kreimer et al. 2005; D'Souza et al. 2007; Syrjanen 2010). 
The evidence for a causal association is strengthened by the infrequency of oncogenic 
viruses in the normal population. Both in Sweden and the USA prevalence is around 
1%, with peaks at ages 30 to 34 and 60 to 64 (Hansson et al. 2005; Gillison et al. 
2012a). Patients with HPV-positive tumors are more likely to be non-smoking, non-
drinking white men of high socioeconomic status (Gillison et al. 2000, 2008; D'Souza et 
al. 2007; Ernster et al. 2007; Chaturvedi et al. 2008; Ang et al. 2010; Guan et al. 2010; 
Liang et al. 2012). Incidence of HPV-positive OPSCC increased by as much as 225% 
from 1988 to 2004 in the USA (Chaturvedi et al. 2011), and in Sweden the proportion 
of HPV-positive OPSCC has doubled each decade since 1970, parallel to the rapid 
increase in incidence (Nasman et al. 2009). An analogous trend in incidence is 
occurring in other western countries (Charfi et al. 2008; Rietbergen et al. 2012), 
including Finland up to this millennium (Syrjanen 2004; Makitie et al. 2006).  
Pathogenesis 
The most common variant of HNSCC is recognized by keratin pearl formation with 
islands of squamous cells surrounded by stromal fibrosis. The less-common ones 
number five: spindle-cell carcinoma with non-cohesive islands of carcinoma resembling 
sarcoma; an exophytic but yet infiltrative non-metastazing verrucous type; papillary 
squamous-cell carcinoma recognizable by a prominent exophytic component; adenoid 
squamous-cell carcinoma; and a solid-lobuled basaloid type with an immature 
appearance, a high nuclear-to-cytoplasmic ratio, and only sparse or no keratinization. 
This last type is highly aggressive, with poor patient outcome (Pai and Westra 2009). 
The striking exception is the HPV-induced tumor with basaloid features but still an 
improved outcome (Adelstein et al. 2009; Pai and Westra 2009). HPV requires 
proliferating basal-layer cells for infection (zur Hausen 2002). Normally, a continuous 
layer of epithelial cells serves as a barrier against HPV infection, but in the pharyngeal 
lymphoid tissue the epithelium is disrupted and the basal membrane exposed, and 
therefore HPV can easily infect the basal stem cells that regenerate the epithelium, 






With the exception of drop-down carcinoma, which develops without epithelial 
dysplasia, HNSCC develops from mild dysplasia in the upper third of the epithelium, to 
moderate dysplasia, and finally to severe dysplasia or carcinoma in situ, involving the 
full thickness of the epithelium (Pai and Westra 2009). When carcinoma breaks through 
the basement membrane, it is classifiable as invasive. During this process, a number of 
genetic and epigenetic changes take place that accumulate in the tumor cell and its 
surroundings. These changes provide the tumor cell with its malignant potential, 
including infinite replicative potential, self-sufficiency in growth signals, insensitivity to 
anti-growth and apoptotic signals, angiogenetic potential, evasion of host immunity, and 
an ability to invade and metastasize (Hanahan and Weinberg 2011). An important step 
in enabling invasion and dissemination is the epithelial-to-mesenchymal transition 
(EMT), a process whereby epithelial cells undergo conversion to pluripotent 
mesenchymal cells, lose cell adherence and polarity, and acquire invasive potential, a 
process directed, amongst other factors, by TGFβ1 (Hanahan and Weinberg 2011).  
 
Two crucial hallmarks in HNSCC carcinogenesis are the p53 and retinoblastoma protein 
(pRb) pathways, both regulators of cell-cycle progression. Tumor suppressor p53 is 
inactivated in a majority of HNSCC cases, either by somatic mutations (60%) or by 
oncoprotein E6 through infection with HPV (20%). Loss of p53 activity results in 
accumulation of DNA mutations that lead to increased genetic instability, and results in 
apoptotic resistance, uncontrolled proliferation, and cell immortalization (zur Hausen 
2002).  
 
In HPV-induced carcinogenesis, the pRb pathway is essential. Normally the binding of 
tumor suppressor p16, an INK4 cell-cycle inhibitor located on chromosome 9p21, to 
cyclinD1-cyclin-dependent-kinase complexes maintains pRb in its hypophosphorylated 
state, in which it binds the E2F transcription factor, thus preventing cell-cycle 
progression. When HPV integrates into the genome, HPV-oncoprotein E7 inactivates 
and degrades pRb, thereby releasing E2F and upregulating both cytoplasmic and nuclear 
p16. As p16 is a G1/S cell-cycle-phase checkpoint regulator, E7 forces the cell into the 
S phase, activating cell proliferation, malignant transformation, and immortalization 
(zur Hausen 2002; Leemans et al. 2011; El-Naggar and Westra 2012). Non-HPV-linked 
genetic alterations associated with HNSCC exist in the p16 gene (CDKN2A), leading to 
lost, diminished, or limited expression of p16 (Thomas and Primeaux 2012). These 
result in development of distant metastases (Namazie et al. 2002) and decreased 
survival (Ambrosch et al. 2001).  
Diagnosis and treatment 
Pre-treatment evaluation 
HNSCC symptoms vary by anatomic location of the primary tumor. Common ones are 
hoarseness, pain, dysphagia, ulcers, and metastatic neck masses (Argiris et al. 2008). 
Based on findings from clinical examination, biopsies, radiologic imaging, and 
confirming histopathology, the tumor is staged according to its TNM classification (in 
15 
 
this thesis AJCC, sixth edition, 2002) where T (Tumor 1-4) represents the size and 
extent of the primary tumor, N (Node 0-3) the absence or presence and extent of 
regional metastatic disease, and M (Metastasis 0-1) the existence of distant metastasis. 
Based on its TNM classification, disease is categorized into Stages I to IV, where Stage 
IV cancers generally have invaded surrounding organs, have a regional metastasis 
greater than 3 cm in size, multiple metastases, or distant metastasis. The TMN 
classification is the most important tool for assessment of prognosis but does not 
include factors such as tumor differentiation (Grade), extra-capsular spread, or 
infiltration depth. Histological grading is based on squamous differentiation (i.e. 
keratinization), degree of cellular pleomorphism, and mitotic index (Thomas et al. 2005; 
Pai and Westra 2009).  
 
Patients with HPV-positive OPSCC often have clinically aggressive disease; typically a 
small primary tumor with nodal metastasis at presentation, often of Stage III or IV 
(Hobbs et al. 2006; Hafkamp et al. 2008; Lewis et al. 2010; Machado et al. 2010). 
Surprisingly, these patients, especially if non-smokers, have a favorable prognosis 
(Ragin and Taioli 2007; Ang et al. 2010; Maxwell et al. 2010; Gillison et al. 2012b). 
Thus, HPV positivity could serve as a prognostic factor for improved survival (Ragin 
and Taioli 2007; Pai and Westra 2009; Ang et al. 2010; O'Rorke et al. 2012). 
Therapeutic options 
Traditionally the standard treatment for HNSCC is surgery including resection of the 
primary tumor and neck dissection in advanced disease. It allows for pathological 
staging, sometimes identifying micrometastasis or extra-capsular spread that will guide 
further treatment decisions. Surgery, however, has its anatomical and functional 
limitations, as surgeons strive for excision both with clear margins and with organ 
preservation. Trans-oral approaches and endoscopic and robotic techniques offer 
functional preservation combined with good oncological results, and microvascular 
flaps make even wider resections possible, although jeopardizing quality of life through 
resultant problems with speech, swallowing, breathing and lack of smell and taste 
(Argiris et al. 2008). To improve quality of life, treatment has moved towards a more 
conservative scheme with organ-sparing RT or CRT as first-line options for certain 
tumor sites. 
 
For the 30 to 40% of HNSCC patients who present with early-stage disease (Stage I-II), 
either surgery, or RT as single modality are options, both resulting in high levels of 
tumor control (Argiris et al. 2008). Adjuvant RT or CRT are options in the case of 
positive or close margins, high T or N class (T3-4, N2-3), bone erosion, perineural 
invasion, or extra-capsular lymph-node infiltration. The typical RT scheme is daily 
fractions of 2.0 Gray (Gy) up to 50 Gy on the primary tumor and regional lymph nodes, 
followed by a booster of 20 Gy on the primary tumor and positive lymph nodes. The 
aim of fractionation is to increase the dose, while minimizing toxicity and risk for 
interruptions (Fu et al. 2000), as the loss of tumor control can reach 14% in only one 
week of interruption (Fowler and Lindstrom 1992). Intensity-modulated radiotherapy 
(IMRT) reduces toxic effects on healthy tissue, protecting it by three-dimensionally 
optimizing the irradiated tumor’s volume (Saarilahti et al. 2005; Argiris et al. 2008). 
IMRT can provide excellent locoregional tumor control (80-95%) and disease-free 
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survival (DFS) (46-95%) in all oral and pharyngeal subsites (Collan et al. 2011; Daly et 
al. 2011; Wang et al. 2012). 
 
Concomitant CT further intensifies the effect of RT (Pignon et al. 2009; Bourhis et al. 
2012). Overall survival (OS) is improved by adding CT to RT especially in OSCC and 
OPSCC (8%) but also in certain hypopharyngeal (HPSCC) and laryngeal cancers 
(LSCC, 5%) (Blanchard et al. 2011). Another meta-analysis demonstrated increased 
survival rates of 20% in locally advanced HNSCC (Cohen et al. 2004) and for these, 
concomitant CRT is often recommended in unresectable, in some nonsurgically treated 
resectable, and in postoperative high-risk patients (Bourhis et al. 2012; Nwizu et al. 
2012). Toxicity increases substantially (Calais et al. 1999; Forastiere et al. 2003), but 
clear recommendations as to schedule, number of cycles, or useful combinations are 
nonexistent (Nwizu et al. 2012). Various agents have a therapeutic effect, but cisplatin 
has become the standard, being well tolerated and radiosensitizing (Cohen et al. 2004; 
Argiris et al. 2008). In Finland, cisplatin is usually administered weekly for 6 weeks at a 
dose of 40 mg/m². Common reasons for dose reduction are renal insufficiency, 
cytopenia, and neutropenic infections.  
Novel agents for cancer treatment have come into clinical use through translational 
research. Cetuximab, a monoclonal antibody for EGFR, is the first molecular-targeted 
agent approved for treatment of locally advanced or metastatic HNSCC in combination 
with RT, or in combination with platinum-based CT for relapsed or metastasized 
disease (Astsaturov et al. 2006).
 
Cetuximab combined with RT raises locoregional 
control and OS (49 vs. 29 months) in locally advanced tumors as compared with RT 
alone (Bonner et al. 2006). Cetuximab is well tolerated but is not considered superior to 
conventional therapy; it mostly serves as a secondary choice for selected cases with 
recurrent cancer (Bonner et al. 2006). 
Complications of radiotherapy and chemoradiotherapy 
Complications of RT and CRT are classified into acute toxicity and late sequelae. The 
late sequelae, including thyroid dysfunction, trismus, subcutaneous fibrosis, and 
osteoradionecrosis, can be minimized by reducing RT fraction dose. The most common 
late complication in HNSCC is xerostomia, at an incidence of 60 to 90% (Wijers et al. 
2002). This results from salivary gland fibrosis and causes significant reduction in 
quality of life through problems with speech and swallowing, altered taste, and dental 
caries (Bhide et al. 2009). The large salivary glands can in part be spared with IMRT 
(Eisbruch 2005; Saarilahti et al. 2005; Saarilahti et al. 2006) but weight loss and 
prolonged use of percutaneous endoscopic gastrostomy as consequences of swallowing 
disorders are still common (Caudell et al. 2009).  
 
Acute toxicity affects tissues that divide rapidly, such as the skin and the mucosa. Skin 
erythema is characterized by vasodilatation and increased permeability that lead to 
reduced perfusion and to vessel- and soft-tissue fibrosis. In HNSCC, skin erythema is 
seldom grave, whereas mucositis occurs in virtually all patients; in its severe form in 
39% of irradiated patients, and in 79% after CRT (Herrstedt 2000). It is the most 
common dose-limiting complication in HNSCC treatment (Calais et al. 1999; Trotti et 
al. 2003). When RT and CT create DNA-strand breaks that, in combination with a 
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cytokine cascade, induce apoptosis of the basal epithelium, mucositis occurs. 
Fibroblasts in the mucosa are damaged, events which cause ulcerations then colonized 
by bacteria (Sonis 2004; Treister and Sonis 2007). These bacteria can easily penetrate 
vessels and, in neutropenic patients, cause septic infections.  
Prevention of mucositis 
Sucking ice cubes during CT is cheap, easy, and to some extent effective in prevention 
of mucositis. No radio-protective drugs have proven effective (Herrstedt 2000; Vissink 
et al. 2003), and some drugs suggested may even compromise survival (Ryu et al. 
2007). Effort should be put into careful planning of treatment, into pain and 
inflammation relief, removal of mucosal-irritating factors, and dental hygiene (Herrstedt 
2000; Vissink et al. 2003; Sonis 2004). TGFβ has been tested in a number of trials for 
its wound-healing effects (Blobe et al. 2000; Flanders and Burmester 2003). TGFβ3 
reduces the incidence of oral mucositis by reducing epithelial cell proliferation 
(Spijkervet and Sonis 1998; Sonis 2004), and orally administered TGFβ2 and TGFβ3 
have reduced CT-induced mucositis both in humans and in animals (Sonis et al. 1997; 
Wymenga et al. 1999; van't Land et al. 2002; Harsha et al. 2006). Thus, TGFβ might 
have the potential to reduce oral mucositis, but this remains to be verified in clinical 
work.  
Survival 
Several articles on HNSCC state that survival has remained static during the most recent 
decades, although all agree that diagnostic and treatment advances have improved 
quality of life (Forastiere et al. 2001; Ragin and Taioli 2007; White et al. 2010; 
Leemans et al. 2011). However, when Carvalho et al. (2005) analyzed the survival trend 
between 1973 and 1999, based on the Surveillance, Epidemiology, and End Results 
(SEER) database which covers about 10% of the US population, they observed an 
increase in the 5-year HNSCC survival rate. This finding was confirmed in 2010, with 
5-year relative survival’s being 55% in 1992-1996 compared to 66% in 2002-2006 
(Pulte and Brenner 2010). Both studies concluded that a vast difference exists between 
anatomic sites with survival reaching only 34% for HPSCC compared to 67% for LSCC 
(Carvalho et al. 2005; Pulte and Brenner 2010). Survival improved the most in cancers 
of the tonsils (40 to 70%), the tongue (45 to 65%), and the oral cavity (54 to 63%), 
followed by NPC (Pulte and Brenner 2010). Survival for lip cancer remained 
unchanged, probably due to its primary high survival rate of 90% (Carvalho et al. 2005; 
Hakulinen et al. 2010; Pulte and Brenner 2010).  
 
In the Nordic countries, the relative survival of HNSCC is among the highest in Europe 
and is still improving (Hakulinen et al. 2010). In Finland during 1995-1999, the 5-year 
OS for OPSCC was 45% and DFS was 67% (Makitie et al. 2006). In Sweden, survival 
for this patient group has improved, especially since the 1980s, for tonsil cancer from 37 
to 62%, and for the base of the tongue from 32 to 51%, whereas age-standardized 
relative survival rates for tongue cancer have improved only insignificantly (42 to 44%) 




When comparing 1964-1968 with 1999-2003 in Finland, 5-year age-standardized 
relative survival of tongue cancer improved from 43 to 50% in men, oral cavity cancer 
64 to 68% and cancer of the pharynx (including NPC, OPSCC, and HPSCC) 26 to 38%. 
In women, the improvement was 55 to 67%, 43 to 69%, and 21 to 51% (Hakulinen et al. 
2010). Women thus have improved survival rates compared with those of men, and also 
a more rapid increase in survival over time. Relative survival tends to be highest among 
young patients, possibly due to a higher proportion of cancers caused by HPV, but as 
their survival has improved also for non-HPV-related cancers, factors such as 
comorbidity and fewer tobacco-smoking years also matter (Hakulinen et al. 2010; Pulte 
and Brenner 2010). Smoking status at diagnosis is a factor for poor prognosis associated 
with treatment response (Fountzilas et al. 1997), survival (Meyer et al. 2008; Duffy et 
al. 2009), and second primaries (Duffy et al. 2009). Although smoking is etiologically 
associated with HPV-negative OPSCC, HPV-positive patients are not exclusively non-
smokers, and also in this prognostically favorable patient group, smoking alters survival 
rates (Hafkamp et al. 2008; Kumar et al. 2008; Gillison et al. 2012b), disease 
recurrence, and risk for second primaries (Maxwell et al. 2010; Gillison et al. 2012b). 
 
Apart from tumor site, the most important predictor for outcome of HNSCC is stage 
(Shah and Lydiatt 1995; Carvalho et al. 2005; Thomas et al. 2005). Average survival of 
high-stage disease is 30 to 40% (Carvalho et al. 2005; Pulte and Brenner 2010). Other 
indicators of poor clinical outcome are positive margins after surgical excision, extra-
capsular spread, and perineural invasion (Quon et al. 2001; Thomas et al. 2005). More 
accurate staging through advanced diagnostic tools, and cancer awareness leading to 
earlier diagnosis may be reasons for improved survival (Carvalho et al. 2005), but Pulte 
and Brenner (2010) found this unlikely, after demonstrating improved survival at all 
stages. 
 
HPV-positive tumors have repeatedly been associated with improved survival 
(Weinberger et al. 2004; Ragin and Taioli 2007; Ang et al. 2010; Dayyani et al. 2010; 
Chaturvedi et al. 2011; O'Rorke et al. 2012). O’Rorke et al. (2012), assessing OS and 
DFS in HPV-positive HNSCC in a meta-analysis that included 52 studies, found both to 
be improved (Hazard ratio, HR, 0.46 for OS and 0.28 for DFS). Similar results are 
demonstrable: HPV-positive OPSCC patients were at 28% lower risk of death than were 
HPV-negative patients, and at a significantly lower risk (51%) for recurrence. In other 
anatomical locations, no difference in OS or DFS emerged (Ragin and Taioli 2007). The 
biological mechanism for this phenomenon remains unknown, but some speculate that 
HPV-positive tumors contain a functioning tumor-suppressor, p53, which renders the 
tumor susceptible to radiation-induced apoptosis, because HPV-positive tumors appear 
more sensitive to both RT and CRT (Dahlstrand et al. 2004; Kumar et al. 2007; Fakhry 
et al. 2008; Kumar et al. 2008; Worden et al. 2008; Ang et al. 2010; Lau et al. 2011). 
After treatment with primary surgery, improved survival has also resulted (Licitra et al. 
2006).  
 
During the last two decades, individualized regimes, combined therapy, and fast-track 
treatment have improved OS and organ preservation (Forastiere et al. 2001). Thus, we 
do have methods for improving survival in HNSCC patients, but we still lack the tools 
for grouping patients according to optimized individual treatment for improved survival, 
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and for risk evaluation of possible de-intensification of treatment protocols (Psyrri et al. 
2012).  
Prognostic markers 
TNM classification has proven insufficient in predetermining a satisfactory treatment 
response in individual patients. The demand is for easily available molecular markers 
that distinguish good responders from bad responders (Thomas et al. 2005). Molecular 
markers could enable personalized treatment; individualized surgical methods, altered 
radiation fractionation schemes, novel combinations of RT, CT, and monoclonal 
antibodies, and de-intensified treatment schemes, all aiming for high survival rates with 
limited side-effects (Quon et al. 2001).  
 
A good prognostic marker is versatile. It identifies patients at risk for aggressive 
disease, predicts therapy response, is noninvasive, and can prove clinically useful as a 
diagnostic tool, in patient counseling, in tailored treatment planning, and in follow-up 
(Quon et al. 2001; Thomas et al. 2005; Singh and Pfister 2008; Shah et al. 2009). Of the 
numerous prognostic markers analyzed, none have proven sufficient, and it is highly 
unlikely that any marker could singlehandedly provide the complete answer to 
treatment-strategy planning. With microarray technology, expression of thousands of 
genes can be investigated simultaneously. Several studies have identified gene profiles 
related to outcome, but none overlap sufficiently for clinical use (Thomas et al. 2005; 
Chung et al. 2006). The only prognostic marker that thus far provides information on 
survival is HPV status. It is therefore vital to combine information on other prognostic 
markers with patient HPV status. These studies evaluated three potential prognostic 
markers: p16 as a surrogate marker for HPV infection, EGFR, and the TGFB1 
polymorphism at rs1800470. 
Several criteria for molecular markers are important regarding the care of HNSCC 
patients. The sample for marker determination should be easily, preferably 
noninvasively, accessible. The method should be sensitive and specific, standardized, 
widely available, and quick (Thomas et al. 2005), not lengthening the time-span from 
diagnosis to treatment that is so vital for survival (Fowler and Lindstrom 1992; Jensen 
et al. 2007). A new method needs to be verified in large, uniformly treated patient 
groups, preferably in prospective studies including anatomically and histopathologically 
homogenous tumors (Thomas et al. 2005).  
Human papilloma virus and p16 
The fact that HPV is a risk factor for OPSCC is recognized, but establishing the mere 
presence of HPV in OPSCC is insufficient for distinguishing causative transcriptionally 
active HPV from a latent infection. Numerous means to detect HPV in tumor cells exist, 
but to date no single method is unanimously accepted. Prevalence reports for high-risk 
HPV infection in HNSCC range from 0 to 100% (Kreimer et al. 2005; D'Souza et al. 
2007), as a result of non-standardized detection methods, differences in type and quality 




Because HPV is an epithelial infection of stratified squamous epithelium, tissue biopsies 
are most useful for its detection. For early detection, applicable methods are direct 
swab, saliva collection, and oral rinsing, but although a large area can be sampled, cell 
collection from the tonsil crypts where HPV supposedly hibernates is uncertain (Kim et 
al. 2007; Venuti and Paolini 2012). As no blood-borne phase exists in HPV infection, 
all blood- and serum samples are by definition surrogate markers. Detection of the 
easily applicable serum antibodies E6, E7, or the structural late-capsid proteins L1 and 
L2 are useful in epidemiological studies, but because HPV can occur in other mucosal 
linings, these are not site specific, but rather represent cumulative exposure to HPV; 
they are therefore of limited utility (Mork et al. 2001; Adelstein et al. 2009). Recent 
findings suggest, however, that antibodies for E6 and E7 in sera could serve as 
prognostic markers for survival and follow-up, post treatment (Rubenstein et al. 2011; 
Liang et al. 2012). 
  
The polymerase chain reaction (PCR) and reverse transcriptase PCR (RT-PCR) amplify 
a signal sequence of DNA or RNA, and are, as methods, vulnerable to segment loss 
during viral integration into host DNA. PCR and RT-PCR, executed with type-specific 
or broad-spectrum primer sets, can discriminate between HPV subtypes, but they are 
extremely sensitive and may not reflect a biologically active infection. They too easily 
amplify HPV from adjacent normal tissue, or from contamination, or amplify non-
transcriptional HPV (Snijders et al. 2003; Adelstein et al. 2009). Quantification meets 
the same issue, although allowing for precise measurement of DNA or RNA, thereby 
distinguishing between integrated and episomal HPV (Venuti and Paolini 2012). The 
sensitivity for qRT-PCR is estimated at 92% and its specificity at 97% (Smeets et al. 
2007). RT-PCR of E6 or E7 mRNA detects transcriptionally active HPV infection and 
is presently considered the gold standard (Venuti and Paolini 2012). It can be performed 
on formalin-fixed paraffin-embedded specimens, but fresh-frozen specimens are 
preferable. This method is time consuming and technically challenging, although it is 
convincingly associated with improved OS and DFS (Shi et al. 2009; Jung et al. 2010; 
Venuti and Paolini 2012). 
  
In situ hybridization (ISH) allows for topographical detection and identification of 
integrated high-risk HPV DNA in tumor cell nuclei and is therefore correlated with 
biologically relevant infection. The method is standardized, technically validated, and 
interpretable with a light microscope, but it is generally type-specific and requires 
multiple probes (Adelstein et al. 2009; Lewis et al. 2010). It has a higher specificity than 
PCR-based methods have, but lacks sensitivity (83%) and may be regarded as 
technically too laborious for routine screening (Smeets et al. 2007; Schache et al. 2011; 
Venuti and Paolini 2012). HPV-DNA ISH has been found to be in high concordance 
with mRNA E6/E7 (Shi et al. 2009), and with a new E6/E7-mRNA ISH method (Ukpo 
et al. 2011), but clinically, ISH is regarded as insufficiently validated. 
 
When HPV oncoprotein E7 degrades pRb, due to a lack of negative feedback, tumor 
suppressor p16 becomes overexpressed. Immunohistochemical (IHC) staining for p16 
can therefore serve as a surrogate marker for transcriptionally active high-risk HPV 
infection. The advantages of p16 IHC over PCR or ISH analysis are its cost 
effectiveness, the commercially available and equally reliable monoclonal antibodies, 
and its simplicity of performance on formalin-fixed paraffin-embedded specimens 
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(Lewis 2012; Thomas and Primeaux 2012). In a p16-positive cell, the nucleus and 
cytoplasm are strongly and diffusely stained, with partial staining uncommon. A 
threshold of 70 to 75% is clinically relevant and has been associated with biologically 
active HPV (Ang et al. 2010; Lewis et al. 2010; Lewis 2012) and improved outcome 
(Weinberger et al. 2004; Reimers et al. 2007; Ang et al. 2010; Lewis et al. 2010). 
Sensitivity for HPV infection has been estimated at 100%, but p16 IHC lacks specificity 
(79%); p16 is expressed in a subset of tumors apparently lacking HPV DNA (Begum et 
al. 2007; Smeets et al. 2007; Ang et al. 2010; Lewis et al. 2010; Schache et al. 2011; 
Thomas and Primeaux 2012). The reason for this is unknown. Theories exist of HPV’s 
being involved in tumorigenesis but later being concealed and p16 overexpressed 
through pRb deletion or suppression, or of p16 overexpression’s being innate, or of p16 
overexpression’s being due to still-unidentified viruses (Lewis et al. 2010; El-Naggar 
and Westra 2012). The p16 false-positive samples can, of course, result from 
variabilities in technical practice and reporting, or can result from the fact that p16 is, 
biomechanically, a surrogate marker (El-Naggar and Westra 2012). 
Epidermal growth factor receptor 
The epidermal growth factor receptor (EGFR) is a transmembrane tyrosine kinase 
receptor, a member of the ErbB/HER gene family. When one of 12 possible ligands 
binds to EGFR, the receptor is autophosphorylated through homo- or 
heterodimerization. Phosphorylation activates multiple signaling pathways that are 
potent oncogenic regulators and lead to cell-cycle progression, apoptosis, and enhanced 
tumor-cell motility, which alter tumor cell growth, invasion, angiogenesis, and 
metastasis (Thomas et al. 2005; Kalyankrishna and Grandis 2006; Moon et al. 2010).  
Overexpression of EGFR in HNSCC is very common (80-92%) (Grandis and Tweardy 
1993; Thomas et al. 2005). Variations exist between anatomical sites; overexpression is 
more common in pharyngeal and oral carcinoma than in LSCC (Takes et al. 1998). 
Expression increases with tumor progression; it is higher in carcinoma than in dysplasia, 
in high- stage disease than in low-stage disease, and in undifferentiated tumors, 
indicating that EGFR plays an important role in HNSCC pathogenesis (Shin et al. 1994; 
Reimers et al. 2007). Smoking can further raise levels of EGFR ligands, causing a 
positive feedback loop for tumor-cell growth (Pai et al. 2002; Du et al. 2005). Smoking 
is directly associated with high EGFR expression, possibly through hypoxia in the 
tumor tissue (Kalyankrishna and Grandis 2006; Kumar et al. 2007, 2008), and in 
smokers with EGFR-overexpressing OPSCC, prognosis is miserable (Kumar et al. 
2008).  
Several reports indicate that in HNSCC, EGFR overexpression is associated with 
clinically aggressive behavior, resistance to treatment, and worse outcome (Huang and 
Harari 2000; Chung et al. 2006; Kumar et al. 2007, 2008; Al-Swiahb et al. 2010; Hong 
et al. 2010). An inverse correlation has been documented between HPV infection and 
EGFR status in OPSCC (Kim et al. 2007; Kumar et al. 2008; Al-Swiahb et al. 2010; 
Hong et al. 2010), although not all studies could confirm this association (Reimers et al. 
2007; Shi et al. 2009).  
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Because EGFR overexpression is common in HNSCC, it would be natural to believe 
that an activating mutation exists, causing the phenomenon. In both colon- and non-
small-cell lung cancers, specific phenotypes responsive to EGFR-targeted treatment 
occur, and EGFR gene copy numbers correlate with RNA and protein expression 
(Lynch et al. 2004; Aiello et al. 2011). In HNSCC, EGFR-activating mutations are rare 
(1-7%) (Lee et al. 2005; Loeffler-Ragg et al. 2006), a connection between gene copy 
numbers and protein expression remains undemonstrated, and the relationship between 
gene copy numbers and outcome is uncertain (Chung et al. 2006; Moon et al. 2010; 
Langer 2012). The molecular mechanisms behind EGFR overexpression are poorly 
understood. However, some patients react to treatment with the RT-modulating 
monoclonal EGFR antibody cetuximab (Huang and Harari 2000; Moon et al. 2010). A 
clinically interesting question is how to determine which patients respond to this type of 
treatment.  
Transforming growth factor β1 
TGFβ is a pleiotropic polypeptide growth factor that virtually all cells both produce and 
have receptors for (Blobe et al. 2000). It regulates important processes that maintain 
homeostasis: proliferation, differentiation, angiogenesis, extra-cellular matrix formation, 
apoptosis, and immunosuppression (Blobe et al. 2000; Akhurst and Derynck 2001). 
 
TGFβ is expressed in three isoforms (TGFβ1-3) with similar but context- and tissue-
dependent effects. In tumor cells, the isoform most frequently upregulated is TGFβ1 
(Derynck et al. 2001); it is secreted and stored in an inactive form in the extra-cellular 
matrix, and is activated only after being cleaved. TGFβ1 signals either through latent 
transcription factors called Smads (canonical signaling, Figure 2) or alternatively, when 
the Smad system is impaired, through non-canonical effector molecules. Both pathways 
are mediated through the cell-surface receptors TGFβRI, II, and III, of which the non-
signaling type III is most abundant. Signaling begins with TGFβ1 binding to TGFβRII 
or TGFβRIII, which recruit, bind, and transphosphorylate TGFβRI. The receptors 
initiate intracellular signaling by phosphorylating, and thereby activating, Smad 2 or 
Smad 3, or both, which then form a complex with Smad 4. The Smad complex moves 
into the nucleus, where it interacts with numerous transcriptional factors, altering the 
fate of the cell (Figure 2) (Blobe et al. 2000; White et al. 2010; Tian et al. 2011).  
 
The noncanonical pathway is stimulated through a growing number of effectors such as 
MAP kinases, growth- and survival kinases, GTP-binding proteins (Ras), and protein 
tyrosine kinases. How TGFβ1 activates these pathways remains unknown, but 
apparently the signaling can override normal growth inhibition (Akhurst and Derynck 





Figure 2  Canonical signaling of TGFβ1. Illustration by Marie Lundberg. 
Transforming growth factor β1 in cancer 
In a healthy cell, TGFβ1 is a potent growth inhibitor through its ability to induce cell 
cycle arrest in the G1 phase, when the cell allows for host-DNA repair or, alternatively, 
induces apoptosis. In early carcinogenesis, TGFβ1 inhibits epithelial cell growth, but 
later, the tumor cells develop resistance to cytostasis and apoptosis, even though the 
TGFβ1 signaling pathway remains intact (Akhurst and Derynck 2001), and they instead, 
when stimulated, proliferate (Tian et al. 2011). When TGFβ1 production is enhanced, 
surrounding tissues are affected: increased deposition of extra-cellular matrix occurs, 
plus altered adhesive properties, enhanced proteolytic activity, angiogenesis, cancer 
stem-cell maintenance, and activation of EMT. These changes influence the tumor’s 
potential to invade and metastasize (Blobe et al. 2000; Akhurst and Derynck 2001; 
Shipitsin et al. 2007; Tian et al. 2011). TGFβ1 activates immortality processes (Tian et 
al. 2011) and affects immunity, both systemically and locally, helping tumor cells evade 
detection by host immunocytes (Blobe et al. 2000; Akhurst and Derynck 2001). 
Multiple molecular mechanisms and pathways are affected, overriding hallmarks of 
carcinogenesis, and in this, TGFβ1 plays an essential role (Tian et al. 2011). The dual 
role of TGFβ1 in carcinogenesis: acting both as a tumor suppressor and tumor 
stimulator, is difficult to understand, and many of its underlying molecular mechanisms 




Transforming growth factor β1 polymorphisms 
The TGFβ1 gene (TGFB1) is located on chromosome 9q13, and polymorphism 
positions are defined relative to the first major transcription site (Figure 3). A number of 
single nucleotide polymorphisms (SNPs) have been identified, of which at least three 
are functional, modulating TGFβ1 plasma levels (Cambien et al. 1996; Awad et al. 
1998; Kaklamani et al. 2005). 
 
  
Figure 3 Locations of the three major TGFB1 single nucleotide polymorphisms. Illustration by 
Marie Lundberg. 
 
Rs1800471 (+G915C) causes an exchange of the large, charged arginine to a small 
neutral proline next to the cleavage site of TGFβ1. The variant genotype is relatively 
rare, its frequency being 7 to 8% in one Czech population (Holla et al. 2002). It is 
associated with decreased production of TGFβ1 in vitro and with decreased lung 
fibrosis (Awad et al. 1998), and with improved survival in gastric cancer (Guan et al. 
2009).  
 
A thymidine (T) exchange to cytosine (C) at position 29 in the signaling sequence of 
TGFB1 results in the substitution of the amino acid leucine (Leu) to proline (Pro). This 
SNP (rs1800470, formerly rs1982073, or +T869C) is localized to the region that directs 
TGFβ transport into the extracellular space. This SNP is very common and is 
documented in several human races and diseases; 16 to 39% of people are of wild-type 
Leu-Leu (TT) genotype, 45 to 61% are Leu-Pro (TC) heterozygotes, and 10 to 43% are 
variant homozygotes (Pro-Pro or CC) (Ziv et al. 2001; Dunning et al. 2003; Ziv et al. 
2003; Ewart-Toland et al. 2004; Shu et al. 2004; Kaklamani et al. 2005; Wei et al. 
2007). In Finland, percentages are reportedly a respective 53, 40, and 7 among breast-
cancer patients, and among controls 51, 42, and 6 (Dunning et al. 2003).  
 
The variant C-allele of rs1800470 has been associated with 2.8-fold higher TGFβ1 
serum levels both in vivo and in vitro (Yokota et al. 2000; Dunning et al. 2003;). The 
polymorphism is in linkage disequilibrium with rs1800469 (C-509T), which is 
accordingly associated with higher TGFβ1 levels (Grainger et al. 1999). The effect may 
therefore result from the combination of these SNPs, but as rs1800469 is situated in a 
non-signaling promoter region, the increased secretion is mainly attributed to rs1800470 
(Dunning et al. 2003; Guan et al. 2009).  
 
The complicated dual role of TGFβ1, functioning both as a tumor suppressor and a 
promotor, is well illustrated in the rs1800470 discussion. Breast-cancer patients carrying 
the C-allele have had a reduced 5-year DFS (Shu et al. 2004). A large multicenter study 
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including 3987 patients and 3867 controls, 1000 of them from Finland, has shown an 
association with an 21% increased risk for the disease (Dunning et al. 2003). The 
researchers estimated that 3% of all breast cancers could be attributable to the variant 
CC phenotype (Dunning et al. 2003). A study from the Netherlands revealed a 1.4-fold 
increased risk for breast cancer for this variant genotype (Gonzalez-Zuloeta Ladd et al. 
2007), but the inverse has also been reported in large case studies (Ziv et al. 2001; Le 
Marchand et al. 2004; Kaklamani et al. 2005). Hishida et al. (2003) found the variant 
allele protective in postmenopausal women and suggested that it is a susceptibility 
genotype confounded by other risk factors, such as hormonal status.  
 
In patients with high TGFβ1-secreting esophageal tumors, overexpression of TGFβ1 in 
IHC staining and reduced expression of TGFβR both associated with high metastatic 
and progressive potential, and decreased survival rates (Fukai et al. 2003; Fukuchi et al. 
2004). An American study failed to affirm any association between rs1800470 and 
survival in gastric cancer (Guan et al. 2009). In prostate cancer, patients with the CC 
genotype at rs1800470 exhibited no significant risk for cancer, but the homozygotes for 
the linkage disequilibrium T-allele of rs1800469 showed a 2.4-fold higher risk for more 
advanced stage cancer (Ewart-Toland et al. 2004), and in a Swedish study, elevated 
production of TGFβ1 was associated with poor clinical outcome (Wikstrom et al. 1998). 
Transforming growth factor β1 polymorphisms in head and neck squamous cell 
carcinoma 
In HNSCC the TGFβ pathway is often disrupted (Garrigue-Antar et al. 1995; Bennett et 
al. 2009; White et al. 2010). Downregulation of TGFβRII (Lu et al. 2006), loss of 
TGFβ1 expression (Logullo et al. 2003), and altered Smad expression (Baez et al. 2005; 
Mangone et al. 2010) are all associated with HNSCC. Surprisingly, few studies address 
TGFB1 polymorphisms in HNSCC.  
 
Two studies explore the polymorphisms rs1800469 and rs1800470 and risk for NPC in 
Chinese populations (Wei et al. 2007; Hu et al. 2012). In the first report, including 108 
NPC patients and 120 matched controls, both variant alleles (rs1800469>T and 
rs1800470>C) were individually associated with an increased risk for NPC, and their 
combination aggravated it (Odds ratio, OR, 1.68) (Wei et al. 2007). The second study, 
four times as large, presented the opposite results concerning rs1800469, and found no 
association between risk and rs1800470 (Hu et al. 2012). Furthermore, the variant allele 
homozygote frequency did vary substantially: 41 and 40% compared to 15 and 24% 
(Wei et al. 2007; Hu et al. 2012). 
 
The C-allele of rs1800470, but not the other two major polymorphisms individually, has 
been associated with HPV16-positive OPSCC in 200 American patients (OR 1.97). 
When all three variant genotypes were combined, this association was even higher (OR 
2.28), indicating that TGFB1 polymorphisms might even form tumor cells susceptible to 
HPV16 (Guan et al. 2010). 
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AIMS OF THE STUDIES 
The general objective of this thesis was to contribute to the search for prognostic 
markers for treatment response in HNSCC. The specific aims of the studies were: 
 To detect a possible correlation between the TGFB1 polymorphism at rs1800470 
and prognosis in HNSCC. 
 To learn whether, in HNSCC patients treated with CRT, rs1800470 of TGFB1 
affects the grade of mucositis and affects treatment time. 
 To assess changes in OPSCC incidence in Finland, and to evaluate the 
correlation of p16 overexpression with this incidence. 
 To discover the inter-relationships of the biomarkers p16, EGFR, and rs1800470 
of TGFB1, and their association with HNSCC patient survival.  
27 
 
PATIENTS AND METHODS 
Patient series (I, II, III, IV) 
Patients included in Studies I to IV were diagnosed and treated for HNSCC at the 
Helsinki University Central Hospital (HUCH) between 1990 and 2007. All studies were 
retrospective. HUCH’s patient records provided data on patient and tumor 
characteristics, treatment, and survival. At the Department of Otorhinolaryngology, 
HNSCC patients who provide written consent donate peripheral blood for future cancer 
research. Those who made up the basis of our studies, the 175 patients in our first study, 
were consecutive donors to this tumor bank. 
.  
Figure 4 Patient selection in Studies I to IV. 
Since the four studies were based on the same patient series, characteristics were 
similar. The majority of the patients were men (74-78%) in all four studies. Mean age 
ranged from 56 (II) to 60 years (I). Tumor site and stage proportions varied to some 
extent among the studies (Table 1). In Study II, only those patients treated with CRT 
were enrolled, which explains the absence there of OSCC and Stage I disease. From 
Studies III and IV we excluded NPC and unknown carcinomas because of the small 
number of samples available. The distribution of more high-staged tumors in Studies III 
and IV compared to Study I is a result of the 40 new OPSCC patients (Figure 4), a 
cohort including all patients at the Department of Oncology treated with IMRT and 




































































Table 1 Tumor sites and stages in Studies I-IV. 
Patient data on smoking, excessive alcohol use, and body mass index were assessed in 
Study I (unpublished data). According to patient records, 115 patients (66%) smoked or 
had smoked, and 36 (21%) used excessive amounts of alcohol. Information on height 
and weight were accessible for 119 patients. Average body mass index was 20.2, 
ranging from 15.0 to 38.2. The data were not further analyzed because of the 
uncertainty and unavailability of facts, due to the studies’ retrospective nature. 
Polymerase chain reaction (I, IV) 
From washed leukocytes, DNA for TGFB1 genotyping was retrieved from the 
peripheral whole blood samples of the departmental HNSCC tumor bank. For real-time 
PCR sequencing of DNA, we used TaqMan chemistry with the ABI Prism 7000 
Sequence Detection System (Applied Biosystems, Foster City, CA, USA). Detection 
primers and probes for genotyping of TGFΒ1 at rs1800470 were purchased from 
Applied Biosystems, according to Dunning et al. (2003), and are listed in Table 2. The 
reaction was performed in a 20µl mixture containing 2x TaqMan Universal Master Mix 
(Applied Biosystems) and 200 nM of primers and probes. The Reporter dye FAM was 
covalently attached to the 5′ end of the E2 probe, and VIC reporter dye to the 5′ end of 
the E6 probe. TAMRA quencher dye served for both probes. Each PCR plate contained 

















Table 2 Primers and probes for rs1800470 of TGFB1. 
Immunohistochemistry (III, IV) 
We attempted to retrieve formalin-fixed paraffin-embedded specimens from all 215 
tumors, but only 142 cases were available, of which 1 unknown primary and 6 NPC 
were excluded to form adequately sized groups (Figure 4). The samples were reviewed 
before IHC at the Department of Pathology, HUCH. IHC staining was performed in a 
LabVision Immunostainer (Labvision, Fremont, CA, USA) at HUSLAB on 5µm tissue 
slices. For epitope retrieval of p16 and EGFR, we used the following antibodies: p16ink 
clone E6H4 (ready-to use, CINtec Histology Kit 9511, MTM Laboratories, Heidelberg, 
Germany) and EGFR (1:25 mouse-clone 31G7, 28-0005, Zymed Laboratories Inc., San 
Fransisco, CA, USA). Diaminobenzidine functioned as the chromogenic reporter in the 
polymer-based detection system (Envision, K5007, DakoCytomation). 
Scoring of immunohistochemical stainings (III, IV) 
All IHC stainings were scored by an experienced pathologist (Prof. I. Leivo) and the 
author (M.L.). Staining of p16 in the tumor cell nucleus and cytoplasm was scored into 
three categories (Figure 5). The staining was positive if more than 70% of the cells were 
stained, intermediate for 30 to 69% staining, and negative if less than 30% were stained. 
Only four tumors (3%) stained intermediately (30-40%) and were therefore combined 
with the negative group. 
EGFR staining of tumor cells was similarly scored into three categories: no staining, 
low staining (≤50%), and high staining (>50%, Figure 5). Intensity of staining was not 
regarded in the classification, and cytoplasmic staining without membrane staining was 
classified as negative. In the analysis, only the high-expressing category (>50%) was 
considered positive according to Reimers et al. (2007). In both IHC experiments, non-




Figure 5  Scoring of p16 and EGFR. A) p16-positive (≥70%), B) p16-negative (30-69%),     
C) p16-negative, D) EGFR-negative, E) EGFR-negative (≤50%), EGFR-positive (>50%). 
Photograph by Docent Jaana Hagström. 
Grading of mucositis and dermatitis (II) 
Information on dose of chemotherapeutic agent and RT, grade and treatment of 
mucositis and dermatitis, treatment time, and interruptions in treatment schedule and 
their reasons came from patient records of the Department of Oncology, HUCH. If 
many evaluations on mucositis and dermatitis were available, the highest grade was 
registered. Mucositis and dermatitis were scored according to the Acute Radiation 
Morbidity Criteria by the Radiation Therapy Oncology Group (RTOG), which includes 
the clinical view and need for analgesics (Table 3) (Cox et al. 1995). Grade 0 is the 
normal baseline and Grade 5 radiation effects leading to death. Scoring can begin from 
commencement of treatment and continues through day 90 when the Criteria of Late 
Effects should be utilized.  
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Skin Follicular, faint, 


















Table 3 RTOG acute radiation morbidity criteria (Cox et al. 1995). 
Incidence and survival (I, II, III, IV) 
Survival data were calculated from date of diagnosis (I, IV), or from the end of 
treatment (II), because the diagnosis date was unavailable at the Department of 
Oncology. OS endpoint was date of death for any reason, or, if alive, the last date of 
follow-up. DFS was defined as the day of tumor recurrence, second primary diagnosis, 
death for any reason, or last date of follow-up (Chua et al. 2005). Survival data were 
updated between studies so that the shortest follow-up time was 2 years (I), extending to 
more than 2.5 years (IV). Mean follow-up time ranged from 3.5 to 4.75 years (I, IV), 
median from 2.9 to 4.75 (II, IV).  
Data on absolute and age-standardized incidence of OPSCC in Finland were provided 
by the Finnish Cancer Registry (Finnish Cancer Registry special tabulation, May 2010). 
For sufficient follow-up time, the last two available decades corresponding to our 
patient material were included: 1989-2008 for absolute and 1987-2006 for age-
standardized incidence.  
Ethical considerations (I, II, III, IV) 
The Research Ethics Board at HUCH approved all study protocols. Because of the 
retrospective nature of these studies, we obtained no informed consent. However, all 
patients had given their voluntary written consent before donating blood samples to the 
tumor bank of the Department of Otorhinolaryngology – Head and Neck Surgery, at 
HUCH. These samples can legally serve in future cancer research. The Research Ethics 
Board approved this proceeding. 
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Statistical aspects (I,II,III,IV) 
Statistical analyses were performed with StatView software (SAS Institute Inc., Cary, 
NC, USA) in Studies I and II, and PASW 18.0 software (SPSS Inc., Chicago, IL, USA) 
in Studies III and IV. Cross-tabulations with chi-square test, or Fisher’s exact test when 
samples were small, were chosen for analyses of contingency variables. With Student’s 
t-test, means across categorical variables were compared. All p-values were two-sided. 
With the Kaplan-Meier method, the OS and DFS across various variables were 
evaluated, with log-rank score determining their statistical significance. The hazard ratio 
(HR) of confounding factors was monitored with the Cox regression model. A p-value 





Transforming growth factor β1 (I, IV) 
In the patient material of Study I, the C-allele frequency of rs1800470 was 29%. Only 
seven patients were CC homozygotes (4%). The CT/CC genotype was most common 
among OPSCC (70%) and LSCC (62%), followed by NPC and HPSCC. The calculated 
C-allele frequency was 39% in OPSCC patients, whereas other anatomic locations 
reached frequencies between 19% (OSCC) and 32% (LSCC, unpublished data). The 
unknown primaries were too few to be rated. The frequencies were similar in Study IV, 
where only 95 patients of the cohort were genotyped, but in Study II, which did not 
include OSCC, the C-allele frequency was somewhat higher (34%). The multivariate 
analysis revealed no correlation between the TGFB1 genotype and gender, age, or stage. 
Mucositis (II) 
The majority (59%) of patients treated with platinum-based CRT suffered from severe, 
Grade 3-4 mucositis, but none had dose-limiting dermatitis. Of the 12 patients (35%) 
who were hospitalized because of CRT-induced infections, only one, suffering from 
varicella zoster infection, had low-grade mucositis. The hospitalization lasted on 
average for 5.5 days (range 3-19), and interfered with treatment schedule in half the 
cases (two each with mucositis or, neutropenic infections, one each with varicella zoster 
or, worsened general condition). The average treatment gap was 8 days (N=8, range 2-
16), and average treatment time was 53 days (range 42-66), only insignificantly shorter 
among patients with low-grade mucositis than in high-grade (52.8 vs. 54.4 days, 
p=0.80). 
 
In this cohort, neither age, gender, cisplatin dose (mg/m²), RT dose (Gy), nor treatment 
mode (three-dimensional RT vs. IMRT) affected grade of mucositis in regression 
analysis, although patients treated with three-dimensional RT tended to suffer from 
higher-grade mucositis (OR 1.90, 95% Confidence Interval, CI, 0.27-13.43, p=0.52), as 
also did carriers of the C-allele (OR 2.65, 95% CI 0.50-13.89, p=0.25). 
p16 (III, IV) 
The p16 expression was assessed in 135 HNSCC tumor specimens, of which 48 (36%) 
were positive. Of 60 OPSCC cases, 41 (68%) overexpressed p16. The frequency of p16-
positive specimens was correlated with decade of diagnosis (1990-1999 vs. 2000-2007), 
with a significant increase from 22 to 41% observed (OR 2.50, 95% CI 1.04-6.03, 
p=0.05, Table 2, Study III). Although the majority of the positive specimens represented 
OPSCC, only five samples were from the former decade, with no significant difference. 
Comparing 2000-2003 and 2004-2007 for OPSCC, the proportion of positive samples 
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increased from 61 to 73%. The percentage of p16 positive samples in other types of 
HNSCC was low: in OSCC and LSCC 6%, and in HPSCC 18%. Those patients with 
p16-positive tumors were on average younger on diagnosis; 55 vs. 60 years (p<0.01). 
This was true also for OPSCC (p=0.01). No significant difference in gender distribution 
existed, but the p16-positive tumors tended to be of higher stage (p=0.09) with a smaller 
primary tumor (T1-2 vs. 3-4, p=0.04), and more regional metastases on diagnosis (N0-1 
vs. N2-3, p<0.001). 
Incidence of oropharyngeal carcinoma (III) 
The age-standardized incidence of OPSCC increased in Finland from 1987 to 2006 for 
both sexes; in total from 0.43 (1987-1991) to 0.85 (2002-2006) per 100 000 person-
years. The corresponding figures for men were 0.68 to 1.2, and for women 0.17 to 0.5 
(Figure 6). During a similar period (1989-2008), the absolute incidence increased from 
0.66 per 100 000 person-years in the first 5 years to 1.36 per 100 000 during the last 5-




Figure 6  Changes in the age-standardized incidence (per 100 000 person-years) of OPSCC 
in Finland during 1987-2006. 
Epidermal growth factor receptor (IV) 
EGFR expression was negative in only 5 tumors (4%), whereas 40 tumors (31%) had 
intermediate staining and 85 (65%) strong staining. The two former categories were 
combined in analysis (Reimers et al. 2007). EGFR was overexpressed in 65 to 80% of 
all cases in all other locations except LSCC that were positive in 42% of cases (p=0.11, 
unpublished data). The co-factors age, gender, stage, and TNM classification were 
unassociated with EGFR expression. The mean age among the EGFR-positive patients 

















































Relations between markers (IV) 
The whole cohort (N=130) was assessed for associations between p16 and EGFR 
without revealing any that were significant (OR 0.85, p=0.70). The tendency was 
towards an inverse correlation, especially in OPSCC where EGFR was overexpressed in 
65% of the p16-positive tumors compared to 79% in the p16-negative group (OR 0.50, 
p=0.37). In the whole cohort (N=130), the corresponding percentages were 63 and 67.  
The variant C-allele of TGFB1 at rs1800470 was more common in the p16-positive 
group, in which 15 of the 20 patients (75%) were carriers, compared to 57% of the p16-
negative patients (Table 4). This association was, however, nonsignificant (OR 2.21, 














TGFB1 wild type     
(TT) N=37 (%) 
5 (14) 32 (86) 23 (62) 14 (37) 
TGFB1 variant 
(CC/CT) N=58 (%) 
15 (26) 43 (74) 34 (59) 24 (41) 
Table 4 The distribution of associations between p16, EGFR, and rs1800470 of TGFB1 
 (N=95). 
Among OPSCC patients, of 16 p16-positive tumors, 14 (88%) were carriers of the C-
allele, whereas allele frequencies were equally distributed among p16-negative tumors. 
Although the association between p16 overexpression and the C-allele was strong 
within the p16-positive cohort, when this was combined with the p16-negative group, 
the result remained nonsignificant (OR 6.00, 95% CI 0.86-41.90, p=0.09). EGFR was 
not associated with the TGFB1 genotype in OPSCC (OR 0.844, p=0.83). 
Survival outcome (I, II, IV) 
The mean OS ranged from 42 months (I) to 57 months (IV). During the longer follow-
up in Study IV, 61% of the patients remained recurrence-free. The recurrences were 
equally distributed across primary sites, with 14, regional nodes with 15, and distant 
metastases also with 15. Seven patients (5%) developed a second primary tumor.  
In HNSCC patients, the variant C-allele of TGFB1 at rs1800470 was significantly 
associated with OS (p=0.02) and DFS (Figure 1 Study I, p<0.05). The results were 
confined to OPSCC (p=0.02) and HPSCC (p=0.04), although LSCC and OSCC also 
demonstrated the same trend (Figure 2, Study I). As a single marker, p16 expression 
was, associated with improved OS (p=0.01) and DFS (p<0.01), independent of age, 
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gender, or stage (HR 0.27, 85% CI 0.11-0.67, p<0.01). This was true in all subtypes of 
cancer, but most convincingly in OPSCC (OS p=0.016, DFS p =0.018, Figure 7). 
 
 
Figure 7 Disease-free survival based on the p16 marker in OPSCC.  
EGFR status did not alter the results. It was not associated with survival (OS p=0.56 and 
DFS p=0.70), or with anatomical site. In multivariate analysis for OS (N=130), EGFR 
status remained unassociated with survival when adjusted for patient age, gender, stage, 
p16 status (N=130, HR 0.97, p=0.85), and TGFB1 genotype (N=95, HR 1.15, p=0.69). 
Tumors overexpressing a combination of p16 and EGFR had the best odds for survival 
(OS p=0.079, DFS p=0.056, Figure 8). 
 
 











As survival was most improved in patients with the variant C-allele of TGFB1 at 
rs1800470 treated with CRT (HR 3.42, p=0.03, Figure 4 and Table 2, Study I) these 37 
patients were analyzed for OS and DFS in combination with p16 status. Kaplan-Meier 
analysis suggested that the combination of the variant C-allele and p16 overexpression 
results in an improved OS and DFS, but that the TGFB1 genotype correlates more 
strongly with survival, because survival was improved among carriers of the variant 
allele independent of p16 status. This finding was verified in multivariate analysis, 
where the carriers of the rs1800470 C-allele had an improved DFS (HR 0.44, p=0.06) 




In this thesis we assessed the correlation between the TGFB1 genetic polymorphism at 
rs1800470 and treatment outcome, and the genotype’s possible relations with prognostic 
markers p16 and EGFR. In patients with various malignant tumors, such as esophageal, 
gastric, lung, and breast cancers, an increased production of TGFβ1 has been associated 
with poor prognosis (Ghellal et al. 2000; Saito et al. 2000; Fukai et al. 2003; Fukuchi et 
al. 2004; Shu et al. 2004). Contrary to what was expected, HNSCC carriers of the 
TGFβ1 high-producing variant C-allele showed improved survival. When stratifying for 
anatomical sites, improved survival was confined to OPSCC and HPSCC, although 
other sites demonstrated the same trend. In further analysis, the TGFβ1-linked effect on 
survival was pronounced in patients treated with CRT; carriers of the variant allele had 
a significantly better outcome (HR 3.42) than the outcome of patients with the wild-type 
genotype. After assessment for overexpression of p16 and EGFR by IHC, analysis 
suggested that CRT-treated carriers of the TGFB1 variant allele whose tumors 
overexpressed p16 showed the best prognosis, but the TGFB1 genotype remained an 
independent prognostic marker for survival. These results did not seem to result from 
aberrant TGFB1 allele frequencies, because similar distributions have emerged among 
healthy individuals in Finland (Dunning et al. 2003), indicating that the SNP is 
unrelated to HNSCC risk.  
The TGFB1 polymorphism at rs1800470 has strengths as a prognostic marker: it is 
accessible from a blood sample and various forms of genetic testing are widely 
available, as are the well-documented oligonucleotides. Genotyping can be executed 
quickly, and problems with storage and possible degradation of DNA can be overcome. 
Results are easy to interpret and independent of interpersonal scoring. The test could be 
standardized and the prospective results could guide the clinician in the treatment 
strategy.  
All our studies had a long follow-up, and the patient series of 175 is, size-wise, fairly 
reasonable for an HNSCC study. The major weakness of this thesis is the highly 
heterogeneous patient material in regard to the anatomic site of the primary tumor, its 
histopathology, and thus the treatment. We inevitably restricted patient numbers by use 
of stratified categories, and therefore the results need confirmation in larger trials. Other 
weaknesses are the retrospective nature of the studies, and the absence of data on 
smoking status, a variable possibly affecting survival endpoints. The lengthy patient-
entry time makes treatment protocols difficult to compare, since treatment regimens 
have changed over time, moving from three-dimensional RT to IMRT, and from 
combined treatment protocols towards more organ-sparing regimens. Although 
rs1800470 is important in TGFβ1 regulation, investigating only one SNP and not 
confirming its consequences for TGFβ1 levels in HNSCC are acknowledged 




Transforming growth factor β1 genotype and survival 
No other studies, to our knowledge, address the impact of the TGFB1 rs1800470 
genotype on survival in HNSCC. The SNP is most thoroughly investigated in breast 
cancer, where results are inconsistent. The variant allele has been associated with both 
decreased (Shu et al. 2004) and increased survival (Gonzalez-Zuloeta Ladd et al. 2007). 
One report states that survival is stage-dependent; in early-stage disease the T-allele was 
associated with higher risk of death but in late-stage disease with lower risk for 
recurrence (Mu et al. 2008). The C-allele has also been associated with risk for late-
stage disease (Shin et al. 2005). We found the beneficial survival figures to be confined 
to Stage IV disease, but when further analyzed, the result was more likely to be a 
function of TGFβ1-induced CRT reactivity, because CRT is usually administered in the 
management of high-stage disease.  
A plausible explanation for our results could be that the TGFβ1 high-producers have 
enhanced tolerance to CRT. We therefore investigated the most significant acute side-
effect in HNSCC treatment, the grade of mucositis, which can cause interruptions in 
treatment, altering outcome. This explanation is not farfetched, because TGFβ1 
participates in wound healing and plays a central role in the mitigation of post-
irradiation injury, its production being activated within one hour after RT (Peterson 
1992). TGFβ has also been topically administered as a CRT-protective agent in multiple 
trials, some of them with positive results (Sonis et al. 1997; Wymenga et al. 1999; van't 
Land et al. 2002; Harsha et al. 2006). This explanation was, however, incorrect in this 
cohort, as the grade of mucositis was similar in both the rs1800470 variant and wild-
type genotype groups. No variations occurred in treatment interruptions or treatment 
time. Apparently, here, TGFβ1 level in sera had no effect on grade of mucositis.  
Possible mechanisms behind response to chemoradiotherapy 
The mechanism behind the enhanced survival of the C-allele carriers treated with CRT 
remains unknown. Although a highly speculative theory, this effect may have been 
mediated through cancer stem cells (CSC). These cells are the main targets of CRT, as 
the quiescent remaining ones presumably cause tumor regrowth and relapse (Eyler and 
Rich 2008; Chen et al. 2009). CSCs are pluripotent cells with properties that include the 
potential to differentiate into heterogeneous tumors, the capability of indefinite self-
renewing, metastasizing, and invading (Jordan et al. 2006). The latter two traits are 
dependent upon the CSC’s inappropriate activation through EMT, a key step in 
embryogenesis in which the cell loses polarity, cell-to-cell, and cell-to-extra-cellular 
matrix contact (Jordan et al. 2006; Eyler and Rich 2008). 
TGFβ interacts with CSCs, maintaining them in breast cancer (Shipitsin et al. 2007). It 
initiates and stimulates EMT in various cancers, including HNSCC cell lines (Mani et 
al. 2008; Yu et al. 2011). In keratinocytes, TGFβ affects CSC differentiation (Schober 
and Fuchs 2011), and in glioblastoma CSCs, its selective inhibition enhances radiation 
response (Zhang et al. 2011). In HNSCC, TGFβ is suggested to crosstalk with the CSC 
transcriptional repressor BMI-1 in vitro, which, when suppressed, enhances survival 
after CRT (Chen et al. 2010; Kim et al. 2010). It is possible that TGFβ1 activates 
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quiescent CSCs, rendering them susceptible to CRT, thereby explaining the improved 
survival. 
Another theoretical possibility is that CRT reactivity is conveyed through TGFβ 
influence on the CSC microenvironment. CSCs are environment-dependent to remain 
undifferentiated and pluripotent (Prince and Ailles 2008). As a large part of HNSCC 
consists of non-parenchymal cells where TGFβ exerts its impact on the extra-cellular 
matrix, on angiogenesis, and on immunosuppression, the CSCs may be sensitized to 
CRT through changes in their environment.  
Transforming growth factor β1 and p16 
Numerous reports have demonstrated improved survival among patients with HPV-
positive tumors (Ragin and Taioli 2007; Kumar et al. 2008; Lassen et al. 2009; Nichols 
et al. 2009; Ang et al. 2010; Dayyani et al. 2010; Chaturvedi et al. 2011; O'Rorke et al. 
2012). Indications also exist of a connection between improved survival and an 
enhanced reactivity to CRT and RT (Kumar et al. 2007; Fakhry et al. 2008; Worden et 
al. 2008; Nichols et al. 2009; Sedaghat et al. 2009; Lassen 2010; Syrjanen 2010). As the 
carriers of the variant C-allele at rs1800470 showed improved survival when treated 
with CRT, we investigated the possible association between the HPV surrogate marker 
p16 and the SNP. 
The result suggested that p16 is an independent prognostic factor in OPSCC, and 
possibly in HNSCC. Furthermore, the p16 overexpression showed no correlation with 
the TGFB1 SNP at rs1800470, and the combination of the two molecular markers 
seemed to predict improved survival. The analysis included only 37 patients, however, 
so the result must be considered preliminary.  
In 2010 Guan et al. published a study in which OPSCC patients with the variant C-allele 
of rs1800470 experienced a doubled risk for developing a HPV16-positive tumor. Our 
series suggested a similar trend, although the association did not reach statistical 
significance. As our patient series was smaller and less homogenous, it is possible that 
the TGFB1 genotype is only a susceptibility marker for HPV infection, and that the 
improved survival of the variant allele reflects the enhanced survival in HPV-induced 
tumors. This would explain why survival was prolonged especially in OPSCC, which 
had the highest frequency of the C-allele and is more likely to harbor HPV. The 
improved survival of the variant allele was, on the other hand, closely associated with 
primary CRT treatment without surgical resection, whereas the increased survival of 
HPV-positive OPSCC seems to be independent of treatment mode. This discrepancy 
argues for rs1800470 as being an independent molecular marker (Licitra et al. 2006; 
Lindquist et al. 2007; Fakhry et al. 2008; Kumar et al. 2008). 
Suggestions are that TGFβ1 and HPV are connected through immunosuppression. An 
HPV infection can be transient or be self-limited. In susceptible cells, infection can 
become permanent and progress into malignancies (zur Hausen 2002). As TGFβ1 is 
involved in suppressing T-helper cells, it may induce an escape from host immune 
surveillance, making the cell susceptible to persistent HPV infection (zur Hausen 2002). 
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In cervical cancer, HPV infection has been suggested to elevate TGFβ1 levels as 
carcinogenesis progresses, altering T-helper cell cytokine expression (Alcocer-Gonzalez 
et al. 2006), which further induces immunosuppression. TGFβ1 levels are additionally 
altered through oncogenes E6 and E7, because they can transactivate TGFβ1 
transcription (Peralta-Zaragoza et al. 2006), and because E7 can block TGFβ1 tumor-
suppressor function (Lee et al. 2002). Apparently TGFβ1 and HPV interact, but whether 
the patient’s genome is associated with a predisposition to HPV infection, with its 
carcinogenic development, or with increased risk for malignant transformation is 
unknown, as is the mechanism behind the enhanced survival after CRT. 
p16 as a prognostic marker 
In this thesis, each tumor’s HPV association was assessed by IHC for p16. Of the 
OPSCC patients, 68% overexpressed p16, which in line with the literature (Charfi et al. 
2008; Ang et al. 2010; Lewis et al. 2010; Lau et al. 2011; Ukpo et al. 2011). Patient 
characteristics and survival accordingly agreed with the literature, as patients with p16-
positive tumors were on average younger with small primary tumors and early nodal 
metastasis, and yet had enhanced survival compared to those with p16-negative tumors 
(Hobbs et al. 2006; Fakhry et al. 2008; Ang et al. 2010; Syrjanen 2010). 
The causative role of HPV in OSCC is controversial, and risk-estimates for HPV 
association range from 0.32 to 363 (Syrjanen et al. 2011). In two systematic reviews, 
HPV prevalence ranged from 24 to 34% (Kreimer et al. 2005; Syrjanen et al. 2011). Our 
results did not confirm a correlation between OSCC and HPV, demonstrating a 
significantly lower p16 overexpression of 5.6%. The p16 positivity of 18% in HPSCC is 
in line with other’s findings (Wilson et al. 2012), whereas 6% in LPSCC is lower than 
high-risk HPV infection-rates reported in one meta-analysis (Kreimer et al. 2005). The 
low detection rates in non-OPSCC cases can be explained by p16’s being validated only 
in OPSCC (Lewis et al. 2012), and by the small sample sizes. The methodological 
variances and the HPV prevalence in non-OPSCC are highly variable in the literature, 
with a lack of case-control studies confirming HPV causativity for non-OPSCC 
(Kreimer et al. 2005; Hobbs et al. 2006; Syrjanen et al. 2011; Torrente et al. 2011; 
Lewis 2012; Lewis et al. 2012; Wilson et al. 2012). 
All single HPV-detection methods show limitations, and the preferable one is disputed. 
For full maximal sensitivity and specificity, algorithms suggested have had p16 IHC 
followed by HPV16 ISH or PCR for p16-positive cases (Smeets et al. 2007; Adelstein et 
al. 2009; Singhi and Westra 2010; Schache et al. 2011; Rietbergen et al. 2012). The 
latter combination correlates 98% with E6 mRNA RT-PCR analysis. Arguments also 
exist of p16’s being a sufficient marker for transcriptionally active HPV infection, 
because HPV-specific tests and p16 IHC are highly correlated; reported discrepancies 
range between 1 and 7% (Weinberger et al. 2004; Ang et al. 2010; Lewis et al. 2010; 
Singhi and Westra 2010; Schache et al. 2011; Thavaraj et al. 2011; Ukpo et al. 2011; 
Lewis 2012).  
Although p16 IHC still lacks standardized criteria for technical performance, scoring, 
and interpretation, it is extensively used, reproducible, cost-effective, easily performed 
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and interpretable. Patients with p16-positive OPSCC have distinct characteristics, and 
show a clinical cancer course divergent from that of p16-negative patients. Most 
importantly, their survival is improved, independent of HPV involvement, by ISH or 
PCR (Weinberger et al. 2004; Begum et al. 2005; Ragin and Taioli 2007; Reimers et al. 
2007; Gillison et al. 2008; Nichols et al. 2009; Ang et al. 2010; Dayyani et al. 2010; 
Lewis et al. 2010; Lewis 2012; Thomas and Primeaux 2012). Therefore, one emerging 
view is that p16 IHC serves as a reliable surrogate marker for high-risk HPV infection, 
and it has been suggested as a relevant marker for determining a patient’s tumor course 
as clinically favorable (Ang et al. 2010; Hoffmann et al. 2010; Lewis et al. 2010; Lewis 
2012), at least for patients with strong p16 expression in basaloid non- or partially 
keratinizing suspected or diagnosed OPSCC (El-Naggar and Westra 2012). But p16 is 
by default a surrogate marker; although providing important prognostic information, it 
cannot be the sole base for randomized treatment studies (Pannone et al. 2007; Smeets 
et al. 2007; Hoffmann et al. 2012; Holzinger et al. 2012; Liang et al. 2012), since false-
positive results can have devastating consequences for patients in clinical de-escalation 
programs. 
In the present studies, detection methods were not compared, and p16-positive samples 
remained unconfirmed by more specific methods. Thus, up to 21% of the positive 
samples may have proven negative in further testing. In this cohort, the p16-positive 
tumors offered a significantly lower risk of death, and risk for recurrence, when 
compared to p16-negative ones, in accordance with findings in the literature. Our 
studies support the evidence of p16 IHC’s being a strong independent molecular marker 
for survival in OPSCC, even though it lacks specificity. 
Epidermal growth factor receptor expression 
The majority of HNSCC cells overexpress EGFR. This was also true in our studies, 
where 96% of the tumor cells expressed EGFR, 65% in more than half of the tumor 
cells. As demonstrated, expression was lower in LSCC than at other sites (Takes et al. 
1998), indicating a differing tumor biology. This overexpression was not associated 
with survival in our analysis. We demonstrated no significant association between 
EGFR and rs1800470 of TGFB1. Although low EGFR expression (<50%) tended to be 
linked to p16 overexpression, the prognostic value of EGFR IHC remained negative. 
Documentation of EGFR expression as being inversely correlated with HPV status is 
not unanimous. Some suggest that the inversely correlated pair could serve as 
prognostic markers for improved OS and DFS (Reimers et al. 2007; Kumar et al. 2008; 
Kong et al. 2009; Hong et al. 2010) whereas others, including our group, cannot confirm 
this (Ulanovski et al. 2004; Kim et al. 2007). 
The differences in techniques, antibody clones, and scoring contribute to the 
disagreement between results. Scoring of EGFR is difficult, with many matters 
unsettled. The threshold for positive samples ranges from 10 to 50% (Reimers et al. 
2007; Al-Swiahb et al. 2010; Hong et al. 2010). For classification, some studies include 
staining intensity, some have formulas for concurrent scoring of intensity and 
frequency, and some use continuous scales (Shin et al. 1994; Chung et al. 2006; Kumar 
et al. 2008). In our studies, the threshold for staining positivity was relatively high 
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(Reimers et al. 2007), enabling a distinction between low and high expression. It is 
possible that a different threshold would have altered the results, but ultimately more 
validation of EGFR IHC is needed before it can serve as a relevant prognostic marker. 
Our heterogeneous population and small subgroups can also explain our lack of 
prognostic validity for EGFR. The association between EGFR and survival is not as 
strong as the association for p16, and therefore in our small patient population we found 
no correlation. 
One interesting fact is that TGFβ is able to transactivate the EGFR pathway (Caja et al. 
2007). In in vivo experiments on HNSCC, cells expressing high levels of TGFβ were 
more resistant to treatment with cetuximab (Bedi et al. 2012), indicating that the TGFB1 
genotype could possibly distinguish among patients who react to treatment with 
monoclonal EGFR antibodies. This needs further study, however. 
Incidence of oropharyngeal cancer in Finland 
OPSCC incidence in the western world is increasing (Tachezy et al. 2005; Hammarstedt 
et al. 2007; Adelstein et al. 2009; Nasman et al. 2009; Warnakulasuriya 2009; Attner et 
al. 2010; Blomberg et al. 2011; Chaturvedi et al. 2011), as in Finland until 2000 
(Syrjanen 2004; Makitie et al. 2006). We have demonstrated that this increase is still 
ongoing, and the rate has become almost three-fold since the 1950’s (Syrjanen 2004). 
The result is obvious both in terms of absolute incidence and age-standardized 
incidence, and for both genders. The result is strengthened by the highly accurate 
nationwide data of the Finnish Cancer Registry, and by the fact that the rates included 
cancers of the base of the tongue, which has not always been the case in OPSCC 
reports. The timespan was indeed only 20 years, but combined with previous Finnish 
reports, follow-up extends to over 50 years.  
Simultaneously with the increase in OPSCC incidence, the proportion of p16-positive 
HNSCC is increasing. Because of a shortage of OPSCC samples from the 1990’s, a 
significant increase in p16-overexpressing OPSCC over time was impossible to 
document, but with a larger population, including not only southern Finland, and a 
longer timespan, it is plausible that this phenomenon could be true also in OPSCC. An 
increase in HPV-related tumors has occurred parallel to OPSCC’s rising incidence, with 
evidence strengthened by diminishing non-HPV-related OPSCC in regions with reduced 
tobacco consumption (Tachezy et al. 2005; Hammarstedt et al. 2006; Nasman et al. 
2009; Attner et al. 2010; Marur et al. 2010; Chaturvedi et al. 2011). HPV-related 
HNSCC may be sexually acquired, because of associations with higher number of 
partners, younger age at sexual debut, and the increasing practice of oral sex (Schwartz 
et al. 1998; Gillison et al. 2000; D'Souza et al. 2007; Heck et al. 2010). HPV prevalence 
is correspondingly increasing in the cervix, although most countries have experienced 
large reductions in cervical cancer incidence after the introduction of effective screening 
programs (Nieminen et al. 1999; Bray et al. 2005). For HNSCC there exists no efficient 
screening. Thus far, non-invasive sampling is uneffective in the oropharynx (Venuti and 
Paolini 2012), and no premalignancies analogous to those found in cervical cancer have 




At the moment, eradication of HNSCC is still out of sight. OPSCC incidence is 
growing, and environmental influences causing chronic inflammation and genetic 
alterations show no signs of diminishing. The HPV vaccines developed against cervical 
cancer could change this situation, as they prevent the same oncogenic HPV types 
causing OPSCC and therefore theoretically could prevent a majority of OPSCC cases. 
In cervical pre-malignancies, vaccination can even cause spontaneous regression, thus 
inhibiting cancer (zur Hausen 2002). It is possible that vaccination for OPSCC would 
have a similar effect, although the existence of potentially malignant HPV-associated 
disorders has been suggested only in OSCC (Syrjanen et al. 2011). In the USA, 
Chaturvedi et al. (2011) estimate that by 2020 we will see more HPV-positive OPSCC 
annually than cervical cancers. This naturally evokes discussion on whether or not to 
start OPSCC vaccine trials, and why not include young men in the HPV-vaccination 
programs? If vaccination proves effective, it will provide the final proof for HPV’s 
being an etiological agent in OPSCC (Haverkos 2004).  
For HNSCC patients, wide heterogeneity exists in clinical outcome. Clinical 
investigation of intensified versus de-intensified treatment schemes combined with 
research into amelioration of toxic effects is warranted, as is research into development 
of new agents for treatment, and identification of biomarkers that can guide treatment 
decisions. The treatment could be even further individually optimized, combining 
surgery, CT, RT, antibodies, and possible new agents and methods with special 
attention to minimizing toxicity and simultaneously eliminating both the tumor and 
CSCs (Psyrri et al. 2012). Hopefully, after assessment in larger trials, the TGFB1 
rs1800470 genotype will, in combination with p16, serve as a prognostic marker for an 




Based on the results presented here, the following conclusions can be drawn: 
 Among HNSCC patients treated with CRT, carriers of the variant C-allele of 
TGFB1 at rs1800470 show improved survival. 
 In HNSCC, the TGFβ1 genotype seems to show no association with grade of 
mucositis after treatment with CRT, or with CRT treatment time. 
 The incidence of OPSCC is rising, and the frequency of p16-overexpressing 
HNSCC tumors in Finland is increasing.  
 Genetic polymorphism at rs1800470 of TGFB1, independent of p16 
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